

Anti-Human IgG (H&L) (Rhodamine Conjugated) Secondary Antibody

Mouse Polyclonal, Rhodamine (TRITC) Catalog # ASR2693

Product Information

Description Anti-HUMAN IgG (H&L) (MOUSE) Antibody Rhodamine Conjugated

Host Mouse

Conjugate Rhodamine (TRITC)

FP Value 2.1 moles Rhodamine (TRITC) per mole of IgG

Target Species Human
Reactivity Human
Clonality Polyclonal

Application DB

Physical State Lyophilized

Host Isotype IgG

Target Isotype IgG (H&L)

Buffer 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Immunogen Human IgG whole molecule

Reconstitution Volume 1.0 mL

Reconstitution Buffer Restore with deionized water (or equivalent)

Stabilizer 10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free

Preservative 0.01% (w/v) Sodium Azide

Additional Information

Shipping Condition	Ambient
Purity	Human IgG (H&L) Antibody Rhodamine Conjugated was prepared from monospecific polyclonal ascites by immunoaffinity chromatography using Human IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Mouse Serum, Human IgG and Human Serum.
Storage Condition	Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Precautions Note	This product is for research use only and is not intended for therapeutic or diagnostic applications.

Images



Dot Blot of Mouse Anti-Human IgG Rhodamine Conjugated Secondary Antibody. Antigen: Human IgG. Load: 3-fold serial dilution starting at 200 ng. Primary antibody: None. Secondary antibody: Rhodamine mouse secondary antibody at 1:1000 for 1H at RT. Block: MB-070 for 1 H at RT.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.